Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Infect Dis ; 21(1): 575, 2021 Jun 15.
Article in English | MEDLINE | ID: mdl-34130662

ABSTRACT

BACKGROUND: A pleural fluid adenosine deaminase (ADA) has been used globally to assist in the diagnosis of a tuberculous pleural effusion (TPE) with a notable negative predictive value. CASE PRESENTATION: We report a case of a patient with a negative pleural fluid ADA who was found to have culture-positive and biopsy-proven Mycobacterium tuberculosis. CONCLUSIONS: This case shows the importance of pursuing gold standard diagnostic studies when clinical suspicion remains high despite negative preliminary testing. We further describe gaps in research to improve pleural fluid biomarkers for TPE.


Subject(s)
Adenosine Deaminase/analysis , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Pleural/diagnosis , Adenosine Deaminase/metabolism , Adult , Antitubercular Agents/therapeutic use , Biomarkers/analysis , Biopsy/methods , Exudates and Transudates , Humans , Male , Pleural Effusion/diagnosis , Pleural Effusion/microbiology , Predictive Value of Tests , Treatment Outcome , Tuberculosis, Pleural/drug therapy , Tuberculosis, Pleural/enzymology
2.
Am J Respir Cell Mol Biol ; 63(3): 374-385, 2020 09.
Article in English | MEDLINE | ID: mdl-32437238

ABSTRACT

Cystic fibrosis (CF) is caused by loss-of-function mutations in the CFTR (CF transmembrane regulator) gene. Pharmacologic therapies directed at CFTR have been developed but are not effective for mutations that result in little or no mRNA or protein expression. Cell therapy is a potential mutation-agnostic approach to treatment. One strategy is to harvest human bronchial epithelial cells (HBECs) for gene addition or genetic correction, followed by expansion and engraftment. This approach will require cells to grow extensively while retaining their ability to reconstitute CFTR activity. We hypothesized that conditionally reprogrammed cell (CRC) technology, namely growth in the presence of irradiated feeder cells and a Rho kinase inhibitor, would enable expansion while maintaining cell capacity to express functional CFTR. Our goal was to compare expression of the basal cell marker NGFR (nerve growth factor receptor) and three-dimensional bronchosphere colony-forming efficiency (CFE) in early- and later-passage HBECs grown using nonproprietary bronchial epithelial growth medium or the CRC method. Cell number and CFTR activity were determined in a competitive repopulation assay employing chimeric air-liquid interface cultures. HBECs expanded using the CRC method expressed the highest NGFR levels, had the greatest 3D colony-forming efficiency at later passage, generated greater cell numbers in chimeric cultures, and most effectively reconstituted CFTR activity. In our study, the HBEC air-liquid interface model, an informative testing platform proven vital for the development of other CF therapies, illustrated that cells grown by CRC technology or equivalent methods may be useful for cell therapy of CF.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Cystic Fibrosis/metabolism , Epithelial Cells/metabolism , Bronchi/metabolism , Cell- and Tissue-Based Therapy/methods , Humans , Stem Cells/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...